Review colon cancer pdf

Diaz-Rubio, E. Oncologist 17 , 15—25 Koeberle, D. Yalcin, S. Oncology 85 , — Hegewisch-Becker, S. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer AIO : a randomised, non-inferiority, open-label, phase 3 trial. Tang, P. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Folprecht, G. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine RAISE : a randomised, double-blind, multicentre, phase 3 study.

Moore, M. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Argiles, G. Cancer 51 , — Regorafenib monotherapy for previously treated metastatic colorectal cancer CORRECT : an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Li, J. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer CONCUR : a randomised, double-blind, placebo-controlled, phase 3 trial. Xu, R. Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Cancer 36 , 97 Siu, L.

Schmoll, H. Hoff, P. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer LUME-Colon 1 : a phase III, international, randomized, placebo-controlled study. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

Chiron, M. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Goede, V. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.

Rigamonti, N. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. Scholz, A. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol.

Kienast, Y. Mueller, T. Efficacy of a bispecific antibody co-targeting VEGFA and Ang-2 in combination with chemotherapy in a chemoresistant colorectal carcinoma xenograft model. Molecules 24 , Hidalgo, M. Mitsuhashi, A. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Incio, J. Goto, H. Fibrocytes: a novel stromal cells to regulate resistance to anti-angiogenic therapy and cancer progression. Semrad, T.

Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy. Jahangiri, A. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Wakelee, H. Efficacy and safety of onartuzumab in combination with first-line bevacizumab- or pemetrexed-based chemotherapy regimens in advanced non-squamous non-small-cell lung cancer.

Lung Cancer 18 , 50—59 Prete, A. Carbone, C. Anticancer Drugs 27 , 29—40 Castro, B. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene 36 , — Liu, T. Stintzing, S. Khattak, M. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.

Colorectal Cancer 14 , 81—90 Arnold, D. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

Tejpar, S. Boeckx, N. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Hecht, J. Colorectal Cancer 14 , 72—80 Wang, Q. Cheng, F.

MET in glioma: signaling pathways and targeted therapies. Demkova, L. Cancer 17 , 26 Lam, B. Bradley, C. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.

Cooper, C. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature , 29—33 Nakamura, T. Molecular cloning and expression of human hepatocyte growth factor. Stoker, M. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility.

Schmidt, C. Xing, F. Activation of the c-Met pathway mobilizes an inflammatory network in the brain microenvironment to promote brain metastasis of breast cancer. Ozawa, Y. BMC Cancer 15 , Anestis, A. Safaie, Q. The c-Met receptor: implication for targeted therapies in colorectal cancer.

Tumour Biol. Otte, J. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 61 , — Matsumoto, K. Cancer Sci. Bahrami, A. C-Met as a potential target for the treatment of gastrointestinal cancer: current status and future perspectives. Cell Physiol. Bouattour, M. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology 67 , — Drilon, A. Blumenschein, G.

Targeting the hepatocyte growth factor-cMET axis in cancer therapy. Cabanillas, M. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II International Thyroid Oncology Group Trial.

Linehan, W. Catenacci, D. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer RILOMET-1 : a randomised, double-blind, placebo-controlled, phase 3 trial. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.

Gao, H. High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis. Luo, H. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.

Baldus, S. Mo, H. Targeting MET in cancer therapy. Chronic Dis. Kentsis, A. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Lennerz, J. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Kammula, U. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. El-Deiry, W. Molecular profiling of 6, colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

Di Renzo, M. Boccaccio, C. Stellrecht, C. MET receptor tyrosine kinase as a therapeutic anticancer target. Comoglio, P. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Pennacchietti, S. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.

Cancer Cell 3 , — Bigatto, V. Qi, J. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Peacock, J. Worzfeld, T. ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis. Malik, M. The Plexin-B family and its role in cancer progression. Stein, U. Parseghian, C. Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies.

Murtuza, A. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Luraghi, P. Van Emburgh, B.

Acquired resistance to EGFR-targeted therapies in colorectal cancer. Viticchie, G. Biomedicines 3 , 46—70 Tanizaki, J. Song, E. Nandagopal, L. Investigational MET inhibitors to treat renal cell carcinoma. Reid, J. Ye, F. Hu, C. Expression of hepatocyte growth factor activator inhibitor-1 HAI-1 gene in prostate cancer: clinical and biological significance.

Buon 19 , — Tsai, C. HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase. Oncogene 33 , — Garajova, I. Ishikawa, T. Matrix metalloproteinase-7 induces homotypic tumor cell aggregation via proteolytic cleavage of the membrane-bound Kunitz-type inhibitor HAI Iveson, T.

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Doi, T. Jones, S. Safety, tolerability, and pharmacokinetics of TAK, a humanized anti-hepatocyte growth factor HGF monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.

Hori, A. Monotherapeutic and combination antitumor activities of TAK, a humanized anti-hepatocyte growth factor neutralizing antibody, against multiple types of cancer. Okamoto, W. TAK, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Merchant, M. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.

Natl Acad. USA , E—E Shah, M. Spigel, D. Cloughesy, T. Randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: efficacy, safety, and hepatocyte growth factor and O 6 -methylguanine-DNA methyltransferase biomarker analyses. Bendell, J. Oncologist 22 , — Pacchiana, G.

Monovalency unleashes the full therapeutic potential of the DN anti-Met antibody. Strickler, J. First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody—drug conjugate targeting c-Met, in patients with advanced solid tumors.

Wang, J. BMC Cancer 16 , Scagliotti, G. Rosen, L. A first-in-human phase I study of a bivalent MET antibody, emibetuzumab LY , as monotherapy and in combination with erlotinib in advanced cancer. Harding, J. Sakai, D. A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. Li, H. Gastroenterology , — Zaman, S.

Remsing Rix, L. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem. Eng, C. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib ARQ plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer.

Rimassa, L. Colorectal Cancer 18 , — Collie, G. Structural and molecular insight into resistance mechanisms of first generation cMET inhibitors. ACS Med. Gan, H. First-in-human phase I study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, pharmacokinetics, and antitumor activity. Yl, W. Properties of FDA-approved small molecule protein kinase inhibitors. Arbour, K. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review.

Lev, A. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.

Choueiri, T. Cabozantinib versus everolimus in advanced renal cell carcinoma METEOR : final results from a randomised, open-label, phase 3 trial. Abou-Alfa, G. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Scott, A. Cabozantinib exhibits potent antitumor activity in colorectal cancer patient-derived tumor xenograft models via autophagy and signaling mechanisms. Yang, S.

Cancer Gene Ther. He, A. First-in-human phase I study of merestinib, an oral multikinase inhibitor, in patients with advanced cancer. Oncologist 24 , e—e Engstrom, L. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models.

Molife, L. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors. Friese-Hamim, M. The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. Dolan, M. Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance.

Yoshioka, H. Ciamporcero, E. Kim, D. Resistance to the c-Met inhibitor KRC induces the epithelial transition of gastric cancer cells. Sharpe, A. The B7-CD28 superfamily. Jelinek, T. Immunology , — Chen, L. Markman, J. Impact of the immune system and immunotherapy in colorectal cancer. Immune Therapy in GI malignancies: a review. Kalyan, A. Updates on immunotherapy for colorectal cancer.

Havel, J. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Cancer 19 , — Grivennikov, S.

Immunity, inflammation, and cancer. Ishihara, J. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Pauken, K. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. Gianchecchi, E. Seidel, J. Rotte, A. Wang, H.

Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy. Berntsson, J. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Gajewski, T. Innate and adaptive immune cells in the tumor microenvironment. Zhang, X. This review provides an overview of existing CRC-targeted agents and their underlying mechanisms, as well as a discussion of their limitations and future trends.

Abstract Colorectal cancer CRC is among the most lethal and prevalent malignancies in the world and was responsible for nearly , cancer-related deaths in Publication types Research Support, Non-U. Citations View Metrics. February 16, Leah H. Brief Report. Ahn, DO; M. Blanke, MD; Alan P. Venook, MD; Robert J. Mayer, MD; Charles S. Nixon, PhD; Richard M. Goldberg, MD; Eileen M. Access through your institution. Add or change institution.